Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gastrointestinal (GI) tract, when referenced in the context of "contrast enhancement," is not a single molecular target or receptor but rather an anatomical region visualized using various contrast agents during imaging procedures. The goal is to improve visualization of the GI tract's structure and function for diagnostic purposes. Contrast enhancement of the GI tract is achieved by administering substances that alter the appearance of tissues on imaging modalities such as X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound. These agents help delineate mucosal surfaces, detect masses, strictures, inflammation, and other abnormalities.
Contrast agents increase radiodensity (X-ray/CT) or alter magnetic properties (MRI) within the GI lumen/wall. Coating mucosal surfaces to highlight structural details. Distending organs with gas or fluid to separate tissue layers. Enhancing blood flow signals with microbubbles during ultrasound.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal Tract (Contrast Enhancement).